Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Treefrog Therapeutics is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, with each matter being handled by a different individual. The portfolio is also spread across 3 distinct art units, indicating a variety of technical focuses within the company's biotechnology filings. VAN BUREN, LAUREN K is the busiest examiner for the portfolio, currently responsible for 1 busiest examiner pending action.
The distribution of 3 pending office actions across 3 distinct examiners and 3 distinct art units suggests that the company's intellectual property is being evaluated independently across different USPTO divisions. Because VAN BUREN, LAUREN K handles 1 busiest examiner pending action, no single examiner dominates the current workload. This structure requires the applicant to address the specific preferences of 3 distinct examiners. The lack of overlap between the 3 distinct art units means that the Biotechnology & Pharmaceuticals applications may cover diverse methodologies or technologies requiring specialized review.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN BUREN, LAUREN K | 1 | 39.8% | +58.1% |
| ABEL, LENORA A | 1 | 68.3% | +34.5% |
| EDWARDS, LYDIA E | 1 | 60.2% | +5.8% |
| PENNINGTON, KATIE LEIGH | 1 | 29.7% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270931 | LARGE CELLULAR MICROCOMPARTMENTS COMPRISING A PLURALITY OF CYSTS | ABEL, LENORA A | — |
| 17634794 | HOLLOW THREE-DIMENSIONAL UNIT MADE FROM RETINAL TISSUE AND USE THEREOF IN THE TREATMENT OF RETINOPATHIES | PENNINGTON, KATIE LEIGH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270924 | CELLULAR MICROCOMPARTMENTS COMPRISING CELLS OF WHICH THE GENOMIC INTEGRITY IS MAINTAINED AFTER AMPLIFICATION AND PREPARATION METHOD | VAN BUREN, LAUREN K | 49d overdue |
| 18270931 | LARGE CELLULAR MICROCOMPARTMENTS COMPRISING A PLURALITY OF CYSTS | ABEL, LENORA A | — |
| 17634794 | HOLLOW THREE-DIMENSIONAL UNIT MADE FROM RETINAL TISSUE AND USE THEREOF IN THE TREATMENT OF RETINOPATHIES | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1799 | 1 |
| 1796 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270924 | CELLULAR MICROCOMPARTMENTS COMPRISING CELLS OF WHICH THE GENOMIC INTEGRITY IS MAINTAINED AFTER AMPLIFICATION AND PREPARATION METHOD | VAN BUREN, LAUREN K | 1638 | §102§103DP | Final Rejection | 49d overdue | Pending | Aug 24, 2023 |
| 18270931 | LARGE CELLULAR MICROCOMPARTMENTS COMPRISING A PLURALITY OF CYSTS | ABEL, LENORA A | 1799 | §102§112 | Final Rejection | — | Pending | Jul 05, 2023 |
| 18347018 | FLUIDIC CHIP AND CELL ENCAPSULATION SYSTEM | EDWARDS, LYDIA E | 1796 | §103 | Final Rejection | 19d | Pending | Jul 05, 2023 |
| 17634794 | HOLLOW THREE-DIMENSIONAL UNIT MADE FROM RETINAL TISSUE AND USE THEREOF IN THE TREATMENT OF RETINOPATHIES | PENNINGTON, KATIE LEIGH | 1634 | §101§102§103§112DPOther | Non-Final OA | — | Pending | Feb 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial